Log In
Friday 25th May 2018

The Top Pharmaceuticals

8th January 2007

14032006_PillPackets1s.jpg1 Global pharmaceutical industry

In 2004 worldwide pharmaceutical sales generated $550M with 75% of the sales generated in 12 countries (US, Japan, Germany, France, Italy, UK, Spain, Canada, Australia, Belgium, Switzerland and South Africa). Global sales are set to grow to $842M by 2010, rising by 6.9% each year. Strong growth is anticipated in N America, Europe, Japan and China, fuelled by key products such as cytostatics (for cancers) and angiotensin-II inhibitors (for high blood pressure).

The top 10 global companies based on 2004 analysis* are:

Company £M Market
Pfizer Inc. (USA) 26,364 9.7%
GlaxoSmithKline Plc. (GB) 17,055 6.3%
Sanofi Aventis Group (France) 14,282 5.3%
Johnson & Johnson (USA) 12,834 4.7%
Merck Sharp & Dohme Inc. (USA) 12,437 4.6%
Novartis AG (Swiss) 11,868 4.4%
Astrazeneca Plc. (GB) 11,257 4.2%
Roche Holding AG (Swiss) 9,222 3.4%
Bristol-Myers Squibb Company (USA) 8,110 3.0%
Wyeth (USA) 7,407 2.7%

* Analysis of 2004 data. Source: Association of the British Pharmaceutical Industry

2 UK pharmaceutical industry

The medicinal and pharmaceutical products market represents a major industry sector in the UK economy. The sector is consistently in the top 3 for generating trade surpluses. In 2005, pharmaceutical exports accounted for £12.2 billion, generating a trade surplus of £3.4 billion. Approximately 73,000 staff are employed directly in the industry and a further 250,000 in related industries.

2.1 Top 10 companies and market share in the UK

The UK market is very fragmented and only two companies have a market share of 10% or more (Pfizer and GlaxoSmithKline). The top 10 companies in the UK only have a market share of 51.4%. The two leading UK companies – GlaxoSmithKline and Astrazeneca are ranked 2nd and 7th in the global top 10 as shown in the following table.

Company Market
Pfizer Inc. 10.7%
GlaxoSmithKline Plc. 9.0%
Sanofi Aventis Group 6.4%
Wyeth 5.2%
Astrazeneca Plc. 5.0%
Novartis AG 3.8%
Roche Holding AG 3.4%
Merck Sharp & Dohme Inc. 2.8%
Lilly 2.7%
Johnson & Johnson 2.4%

2.2 UK’s top 10 pharmaceutical products and sales value

Pharmaceutical companies carry out nearly a quarter of all industrial research and development in the UK. They spend more than 20% of their gross output on R&D and invested £3.2 billion in 2004. On average, it takes 10-12 years and £550 million to develop a new medicine, with no guarantee of commercial success.

The top 10 products listed below accounted for sales of £1,956M.

Product £M
Lipitor - Cholesterol 493
Seretide – Asthma 279
Zoton – Gastro-intestinal disorders 225
Plavix – Thrombosis 179
Omeprazole - Gastro-intestinal disorders 159
Zyprexa – Schizophrenia 152
Simvastatin – Cholesterol 124
Efexor – Depression 124
Enbrel – Rheumatoid arthritis 115
Cozaar – Hypertension 106

3 Profiles of top 10 companies in UK

Pfizer is a research-based, global pharmaceutical company which develops, manufactures and markets leading prescription-only medicines for humans and animals. It also has a wide portfolio of consumer healthcare products.

The company employs 122,000 people in 60 countries and has sales in more than 150 countries. It has major R&D facilities worldwide. In 2004, overall investment in R&D is estimated at $7.9 billion - the largest investment of any pharmaceutical company, and of any private sector research institution, in the world.

GlaxoSmithKline (GSK) employs 100,000 people in 116 countries, with over 15,000 people working in R&D. The company produces medicines which treat six major disease areas – asthma, virus control, infections, mental health, diabetes and digestive conditions. It is also the only pharmaceutical company to tackle the World Health Organisation’s three ‘priority’ diseases – HIV/AIDS, tuberculosis and malaria.

Sanofi Aventis has c. 100 000 employees worldwide and a presence in 100 countries throughout the 5 continents. It focuses on 7 major therapeutic areas namely cardiovascular, thrombosis, metabolic disorders, oncology, central nervous system, internal medicine and vaccines. Its’ R&D investment is more than 4 billion euros each year.

Wyeth is a global leader in prescription pharmaceuticals, non-prescription consumer health care products, and pharmaceuticals for animal health.

Wyeth's products are sold in more than 145 countries, and its product portfolio includes innovative treatments across a wide range of therapeutic areas. The company’s employs 52,000 staff and has manufacturing facilities on four continents. Wyeth has a unique research and technology base encompassing small molecules, biopharmaceuticals, genetic engineering which should provide the next wave of innovative therapies and vaccines.

Astrazeneca employs over 65,000 people worldwide: 58% in Europe, 28% in the Americas and 14% in the rest of the world. Their products tackle key areas of medical need such as cancer, cardiovascular, gastrointestinal, infection, neuroscience and respiratory & inflammation.

In 2005 the company’s total R&D spend was $3.4Bn. 12,000 people work in R&D at centres in Sweden, the UK, the US, Canada, France, India and Japan. Some 14,000 people at 27 manufacturing sites in 19 countries are involved in producing our product range.
Novartis was created in 1996 through the merger of Ciba-Geigy and Sandoz. The company has 4 divisions:

• Pharmaceuticals - prescription medicines.

• Vaccines and Diagnostics - development of preventive treatments and tools.

• Sandoz - generic prescription drugs.

• Consumer Health - OTC, Animal Health, Medical Nutrition, Gerber (formerly Infant & Baby) and CIBA Vision.

Novartis is the only company with leadership positions in both patented and generic pharmaceuticals.

Roche has 2 divisions - Roche Pharmaceuticals and Roche Diagnostics. They have a broad range of products and services ranging from the emerging fields of screening and early detection to prevention, diagnosis, therapy and treatment monitoring.

The Pharmaceuticals division is the leading provider of innovative products in oncology, transplantation and hepatitis. In 2005 the division invested just under 5 billion Swiss francs in R&D. The company makes extensive use of biotechnology; 5 of their 10 top selling medicines are manufactured using biotechnology. Biopharmaceuticals account for over 50% of drug sales.

The Diagnostics division is one of the world’s largest diagnostics businesses with 20% of the IVD market. These diagnostic tools have a wide range of healthcare applications – from early detection of disease, to diagnosis, through to selecting and monitoring treatment. In 2005 the division invested 700 million Swiss francs in R&D which is focusing on discovering and developing new disease markers. It is anticipated that diagnostic tools will play a growing role in ensuring that patients are correctly diagnosed as early as possible and receive the right treatments.

Merck Sharp & Dohme is a global research-driven pharmaceutical company. It has approximately 61,500 employees and conducts research at 10 major research centres worldwide, manufactures products in 31 facilities, and operates in more than 140 countries.
Merck’s product line includes a broad portfolio of highly innovative prescription products in important therapeutic areas. These include medicines to treat high blood pressure, elevated cholesterol levels, osteoporosis, asthma, benign prostatic hyperplasia, arthritis, migraine, glaucoma, emesis, infectious diseases (antibacterial, antifungal, and antiviral agents), and vaccines to prevent childhood diseases and hepatitis A and B. In 2005 worldwide sales were $22 billion, with $3.8 billion invested in R&D.

Lilly is a worldwide company which employs 42,000 employees. Its leading medicines focus on treating conditions such as schizophrenia, diabetes, cancer, osteoporosis, attention deficit hyperactivity disorder, erectile dysfunction, severe sepsis, depression and bipolar disorder.
The company invests just under 20% of total sales back into R&D – this is the highest proportion in the sector. In 2004 this amounted to £76 million in the UK alone. It has 8,336 employees engaged in R&D. Clinical research conducted in more than 50 countries with R&D facilities in 9 countries.

Johnson & Johnson is the world's most comprehensive and broadly-based manufacturer of health care products. It comprises 230 companies worldwide, marketing health care products throughout the world. It employs 115,700 people in 57 countries and the portfolio of companies produce thousands of products in the following business areas:

• Consumer.

• Medical devices and diagnostics.

• Pharmaceuticals.

Products range from baby care, first aid and hospital products to prescription pharmaceuticals, diagnostics and products relating to family planning, dermatology and feminine hygiene.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

M3 - For secure managed hosting over N3 or internet
© Mayden Foundation 2018